Correction to Lancet Respir Med 2025; published online June 24. https://doi.org/10.1016/S2213-2600(25)00213-9

No authors listed

Published Erratum

No authors listed. Lancet Respir Med. 2025 Sep.

. 2025 Sep;13(9):e50.

doi: 10.1016/S2213-2600(25)00266-8. Epub 2025 Jul 18.

No abstract available

Erratum for

Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
Spigel DR, Westeel V, Anderson IC, Greillier L, Guisier F, Bylicki O, Badin FB, Rousseau-Bussac G, Deldycke C, Griesinger F, Bograd A, Zhong W, Le Treut J, Van Hulst S, Gandara DR, Reck M, Hoffknecht P, Gubens MA, Crowley J, von der Leyen H, Woodard GA, Jablons DM, Kratz JR, Mann MJ; AIM-HIGH investigators. Spigel DR, et al. Lancet Respir Med. 2025 Oct;13(10):887-896. doi: 10.1016/S2213-2600(25)00213-9. Epub 2025 Jun 24. Lancet Respir Med. 2025. PMID: 40578381 Clinical Trial.